In vitro and in vivo applications of a universal and synthetic thermo-responsive drug delivery hydrogel platform

• Published in: International journal of pharmaceutics 2023-03, Vol.635, p.122777-122777, Article 122777
• Main Authors: Gholizadeh, Hanieh, Landh, Emelie, Silva, Dina M., Granata, Antonella, Traini, Daniela, Young, Paul, Fathi, Ali, Maleknia, Simin, Abrams, Terence, Dehghani, Fariba, Xin Ong, Hui
• Format: Article
• Language: English
• Subjects: Animals; BMP2; Ciprofloxacin HCl; Drug Delivery Systems; Humans; Hydrogels - chemistry; In situ hydrogel; Polyethylene Glycols - chemistry; Polymers - chemistry; Sustained drug release; Synthetic Drugs; TGF-β1; Thermo-responsive polymer; TNF-α
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2023.122777

[Display omitted] A synthetic and thermo-responsive polymer, poly(N-isopropylacrylamide)-co-(polylactide/2-hydroxy methacrylate)-co-(oligo (ethylene glycol)), is used to formulate a universal carrier platform for sustained drug release. The enabling carrier, denoted as TP, is prepared by dissolving the polymer in an aqueous solution at a relatively neutral pH. A wide range of therapeutic moieties can be incorporated without the need for the addition of surfactants, organic solvents, and other reagents to the carrier system. The resulting solution is flowable through fine gauge needle, allowing accurate administration of TP to the target site. After injection, TP carrier undergoes a coil to globe phase transition to form a hydrogel matrix at the site. The benign nature of the polymer carrier and its physical gelation process are essential to preserve the biological activity of the encapsulated compounds while the adhesive hydrogel nature of the matrix allows sustained elusion and controlled delivery of the incorporated therapeutics. The TP carrier system has been shown to be non-toxic and elicits a minimal inflammatory response in multiple in vitro studies. These findings suggest the suitability of TP as an enabling carrier of therapeutics for localized and sustained drug delivery. To confirm this hypothesis, the capabilities of TP to encapsulate and effectively deliver multiple therapeutics of different physicochemical characteristics was evaluated. Specifically, a broad range of compounds were tested, including ciprofloxacin HCl, tumor necrosis factor-alpha (TNF-α), transforming growth factor beta 1 (TGF-β1), and recombinant human bone morphogenetic protein 2 (BMP2). In vitro studies confirmed that TP carrier is able to control the release of the encapsulated drugs over an extended period of time and mitigate their burst release regardless of the compounds’ physiochemical properties for the majority of the loaded therapeutics. Importantly, in vitro and in vivo animal studies showed that the released drugs from the TP hydrogel matrix remained potent and bioactive, confirming the high potential of the TP polymer system as an enabling carrier.